Literature DB >> 17111206

The U.S. Thrombosis and Hemostasis Centers pilot sites program.

N F Dowling1, M G Beckman, M Manco-Johnson, K Hassell, C S Philipp, L A Michaels, S Moll, J A Heit, J Penner, R Kulkarni, S Pipe, P Bockenstedt, J Andersen, S Crudder, A H James, S Zimmerman, T L Ortel.   

Abstract

Venous thromboembolism (VTE) is a common disorder associated with significant morbidity and mortality. Despite important advances in understanding the etiology of VTE, delivery of care to patients with thrombosis and thrombophilia is frequently incomplete and highly variable. A comprehensive model of health care has been used successfully to treat and prevent complications for people with hemophilia and other chronic disorders. The effectiveness of an integrated healthcare model for patients with all coagulation disorders has yet to be evaluated. The Division of Hereditary Blood Disorders of the Centers for Disease Control and Prevention (CDC) is collaborating with eight Thrombosis and Hemostasis Centers (pilot sites) to provide health-related services and conduct research directed toward the reduction or prevention of complications of thrombosis and thrombophilia. The initial objectives of the collaboration are to (1) determine the efficacy of integrated multidisciplinary care and prevention services for people with hemostatic disorders, (2) assess unmet needs for service delivery and identify outreach strategies to improve access to care, (3) develop effective messages aimed at disease management and prevention, and (4) foster the development of training programs to enhance provider skills for the delivery of patient care. To address these objectives, the investigators and CDC have developed and implemented a web-based patient registry to follow prospectively service allocation and patient outcomes. Funding for the program began in October 2001. All eight funded centers are affiliated with U.S. medical schools. Principal investigators at the centers are hematologists (five adult, two pediatric) or cardiologists. Faculty in obstetrics-gynecology, surgery, and multiple other specialties are integral to the model of care at the centers. Other critical components at the centers are clinical laboratory services, training programs, research networks, and education and outreach programs. From August 2003 to March 2006, over 2,600 patients were enrolled in the registry, accounting for a total of more than 5,000 visits to the centers. Immediate goals of the data collection at the centers are to characterize patients receiving care at centers and document the state of health services provided. Long-term goals are to evaluate prospectively clinical outcomes for patients receiving multidisciplinary care and prevention services at centers. The network of data collection across centers will facilitate future collaborative clinical and epidemiologic investigations and enhance collective expertise in hemostasis and coagulation disorders.

Entities:  

Mesh:

Year:  2007        PMID: 17111206     DOI: 10.1007/s11239-006-9002-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  14 in total

Review 1.  The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs.

Authors:  M Andrew; A D Michelson; T Bovill; M Leaker; P Massicotte; V Marzinotto; L A Brooker
Journal:  J Pediatr Hematol Oncol       Date:  1997 Jan-Feb       Impact factor: 1.289

2.  Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.

Authors:  C H van Ommen; H Heijboer; H R Büller; R A Hirasing; H S Heijmans; M Peters
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

3.  Neonatal symptomatic thromboembolism in Germany: two year survey.

Authors:  U Nowak-Göttl; R von Kries; U Göbel
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

4.  A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders.

Authors:  Judith R Baker; Sally O Crudder; Brenda Riske; Val Bias; Ann Forsberg
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

5.  Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.

Authors:  Ruby Anne E Deveras; Craig M Kessler
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

6.  On the relationship between changes in the deep veins evaluated by duplex sonography and the postthrombotic syndrome 12 years after deep vein thrombosis.

Authors:  U K Franzeck; I Schalch; A Bollinger
Journal:  Thromb Haemost       Date:  1997-06       Impact factor: 5.249

Review 7.  Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Mark N Levine; Gary Raskob; Rebecca J Beyth; Clive Kearon; Sam Schulman
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

9.  The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic disease.

Authors:  Alex C Spyropoulos; William Haire
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

10.  Knowledge and educational needs of individuals with the factor V Leiden mutation.

Authors:  E A Hellmann; N D Leslie; S Moll
Journal:  J Thromb Haemost       Date:  2003-11       Impact factor: 5.824

View more
  5 in total

1.  Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism.

Authors:  Deborah A Lewis; Gregg J Stashenko; Olga M Akay; Lulit I Price; Kouros Owzar; Geoffrey S Ginsburg; Jen-Tsan Chi; Thomas L Ortel
Journal:  Thromb Res       Date:  2011-07-07       Impact factor: 3.944

2.  Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.

Authors:  Deborah A Lewis; Sunil Suchindran; Michele G Beckman; W Craig Hooper; Althea M Grant; John A Heit; Marilyn Manco-Johnson; Stephan Moll; Claire S Philipp; Kristy Kenney; Christine De Staercke; Meredith E Pyle; Jen-Tsan Chi; Thomas L Ortel
Journal:  Thromb Res       Date:  2015-02-07       Impact factor: 3.944

3.  Characteristics of abdominal vein thrombosis in children and adults.

Authors:  Daniel Landi; Michele G Beckman; Nirmish R Shah; Paula Bockenstedt; Althea M Grant; John A Heit; Nigel S Key; Roshni Kulkarni; Marilyn Manco-Johnson; Stephan Moll; Claire S Philipp; Judith C Andersen; Thomas L Ortel
Journal:  Thromb Haemost       Date:  2013-02-14       Impact factor: 5.249

4.  Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome.

Authors:  Claire S Philipp; Ambarina S Faiz; Michele G Beckman; Althea Grant; Paula L Bockenstedt; John A Heit; Andra H James; Roshni Kulkarni; Marilyn J Manco-Johnson; Stephan Moll; Thomas L Ortel
Journal:  Thromb Res       Date:  2013-11-01       Impact factor: 3.944

Review 5.  Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions.

Authors:  Jinlei Li; Thomas Halaszynski
Journal:  Local Reg Anesth       Date:  2015-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.